Quality of Life in Patients Having a Prosthetic Joint Infection (QuaVIPA)
Bone and joint infections (BJI) are rare serious pathology which can lead to a very heavy handicap and sometimes to the life threatening. These are devastating diseases whose diagnosis is difficult. They are known to be associated with high mortality rates (5%) and significant morbidities responsible for functional sequelae (40% of patients) with an individual cost (prolonged hospitalization, altered quality of life) and societal (work stoppage, partial or total disability, temporary or permanent) extremely high.
These bone and joint infections have a significant impact on the quality of life of those affected who, in addition to their infection, are reduced in their autonomy and often need to be taken care of outside their home, sometimes away from home.
To the knowledge of investigators, there are few studies on the measurement of quality of life in patients with osteoarticular infection.
The aim of this study is to implement the EQ-5D-3L validated quality of life questionnaire and the EVA scale (created by EuroQol Group) for each patient with a prosthetic joint infection (IPA) on prosthesis during their medical care in the department of Infectious and Tropical Diseases.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Tristan FERRY, MD, PhD
- Phone Number: +33 04 72 07 11 07
- Email: tristan.ferry@chu-lyon.fr
Study Contact Backup
- Name: Eugénie MABRUT
- Phone Number: +33 04 26 73 29 38
- Email: eugenie.mabrut@chu-lyon.fr
Study Locations
-
-
-
Lyon, France, 69004
- Recruiting
- Centre de reference des infections ostéo-articulaires de Lyon
-
Contact:
- Tristan FERRY, MD, PhD
- Phone Number: +33 04 72 07 11 07
- Email: tristan.ferry@chu-lyon.fr
-
Contact:
- Eugénie MABRUT
- Phone Number: +33 04 26 73 29 38
- Email: eugenie.mabrut@chu-lyon.fr
-
Principal Investigator:
- Tristan FERRY, MD, PhD
-
Sub-Investigator:
- Sebastien LUSTIG, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient having prosthetic joint infection
- Patient who did not object to participate in the study
- Patients over 18 years of age
Exclusion Criteria:
- Patient with additional psychological or psychiatric support outside the service.
- Patient benefiting from a system of legal protection (safeguard of justice, guardianship, curatorship)
- Patient participating in another study on measuring quality of life
- Patients with cognitive impairment to understand the questionnaire
- Impossibility of giving the patient informed information
- Patients with no infection diseases follow up at the CROIX ROUSSE hospital
- Patients with amputation as initial surgery for infection management
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients having prosthetic joint infection
The primary aim is to measure the evolution of quality of life in patients having prosthetic joint infection during their medical care and possibly psychologic assistance in the Infectious and Tropical Diseases Department of Croix-Rousse Hospital.
|
Patients will complete two EQ-5D-5L and EQ-5D-3L quality of life questionnaires and will complete an analog visual scale during each of their follow-up visits to the Infectious and Tropical Diseases Department of Croix-Rousse hospital.
No visits will be added to complete the questionnaires.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Questionnaire EQ-5D-3L
Time Frame: 12 to 24 months
|
EQ5D is one of the most widely used health states descriptive system and has a valuation in France. EQ-5D questionnaires have 5 dimensions: "Mobility", "Human Autonomy," "Current Activities", "Pain / Discomfort", "Anxiety / Depression" and all dimensions are described by 3 problem levels corresponding to patient response choices. A quality of life score is obtained according to the answers to the questionnaires. |
12 to 24 months
|
|
Analog Visual Scale
Time Frame: 12 to 24 months
|
Use of a Analog Visual Scale to measure the quality of life
|
12 to 24 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Questionnaire EQ-5D-5L
Time Frame: 12 to 24 months
|
In the EQ-5D-5L the 5 dimensions are described by 5 problem levels corresponding to patient response choices. A quality of life score is obtained according to the answers to the questionnaires. In France, only the EQ-5D-3L has been validated, not yet the EQ-5D-5L which has only been translated. In this study investigators want compare the score obtained to the questionnaires EQ5D-5L and EQ-5D-3L to determine if EQ-5D-5L is more adapted to patients having prosthetic joint infection. |
12 to 24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 69HCL17_0419
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Quality of Life
-
NCT07378215RecruitingQuality of Life | Postoperative Quality of Recovery | Health-Related Quality-of-Life
-
NCT04239183UnknownQuality of Life of Colostomized Patient
-
NCT02901639UnknownImproving Quality of Life
-
NCT04761367CompletedImprove Quality of Life
-
NCT05722249CompletedProfessional Quality of Life
-
NCT01784497CompletedHealth Related Quality of Life
-
NCT01269489UnknownHealth-related Quality of Life
-
NCT01247636CompletedHealth-Related Quality of Life
-
NCT06014671CompletedBreif Description: Patients' Quality of Life of
Clinical Trials on Quality of life
-
NCT04334096CompletedQuality of Life | Breast Cancer | Breast Neoplasms
-
NCT01228864Terminated
-
NCT01325753WithdrawnLung Metastases | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma
-
NCT04670874RecruitingCutaneous Lymphoma
-
NCT04551378RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 Infection
-
NCT04650178Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Neuropathy | COVID-19 Infection
-
NCT00791635Active, not recruitingCervical Carcinoma | Endometrial Carcinoma | Vaginal Carcinoma | Malignant Female Reproductive System Neoplasm | Vulvar Carcinoma
-
NCT04500600Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 Infection
-
NCT03057639Terminated
-
NCT04096417Active, not recruitingMetastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | FGFR1 Gene Amplification